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Metal-on-metal (MoM) total hip arthroplasties (THAs) gained popularity during the 1990s due to the theoretical advantages of lower wear and a decreased rate of dislocation. 1 However, by 2010 it became clear that these implants were associated with a high rate of revision and adverse local tissue reactions (ALTRs). 2 Approximately 93 000 patients underwent surgery with the Articular Surface Replacement (ASR) Hip System (DePuy Orthopaedics, Warsaw, Indiana) before its recall in 2010, due to higher than expected rates of revision at five years. 3 Current guidelines on the follow-up of MoM components consist of clinical evaluation, repeated measurement of the levels of metal ions in the blood, radiographs and soft-tissue imaging when needed. [4] [5] [6] There is little information about the repeated measurement of levels of metal ions. There is, however, some evidence that the level of cobalt ions in the blood increase after ASR THA. 7 There is no clear cutoff limit on the levels of metal ions in the blood that would be sensitive and specific in predicting ALTR. 8 Due to this lack of data, the Food and Drug Administration in the United States does not provide strict recommendations on how often the levels of metal ions in the blood should be measured. 4 The main purpose of this study was to determine whether there was change in the levels of metal ions in the blood at mid-term follow-up in these patients. The second aim was to evaluate possible confounding factors affecting changes in the levels of metal ions.
Patients and Methods
A total of 1721 patients (1950 hips) who underwent hip implantation with the ASR Hip System were enrolled in a prospective, multicentre study, between May 2012 and June 2015, following the voluntary recall of this system. Patients were followed annually for five years, or until revision. Annual review included the measurement of the levels of chromium (Cr) and cobalt (Co) ions in whole blood, patient-reported outcome measures (PROMs), and anteroposterior and shoot through lateral radiographs of the hips. Whole blood measurements of the metal ions were taken at certified, local laboratories. All information about the patients was reported to a single institution from 16 sites in six countries. The abduction and anteversion angles of the acetabular component were measured from digital plain radiographs using mDesk software (RSA Biomedical, Umeå, Sweden). Inclusion criteria consisted of any patient with either the MoM hip resurfacing arthroplasty (HRA) version of the ASR or the MoM THA version (ASR XL) implanted at time of enrolment. Included patients also had the ability to give informed consent as approved by the ethics committee, and state willingness to return for a period of five years.
For our analyses, we defined early and mid-term periods of follow-up as less than and more than seven years, respectively. Therefore, additional inclusion criteria included: any patient who was enrolled earlier than seven years post-operatively who had at least one follow-up visit later than seven years post-operatively; and did not have a contralateral 332 patients with incomplete data at enrolment (n = 387 hips) 1389 patients enroled in study with complete enrolment data (n = 1563 hips) 1337 patients with complete enrolment data able to return for follow-up (n = 1494 hips) 529 patients with required enrolment and follow-up data (n = 582 hips) 476 unilateral patients with all required data (n = 476 hips) 53 bilateral patients (n = 106 hips) 11 patients with visits less than 1 yr apart (n = 11 hips) 435 unilateral patients in final cohort (n = 435 hips) 6 patients with developmental dysplasia of the hip (n = 6 hips) 1721 ASR hip resurfacing and total hip arthroplasty patients undergoing follow-up from 2012 to 2016 from 16 different sites in 6 countries (n = 1950 hips) 52 patients deceased or with withdrawn consent after enrolment (n = 69 hips) 808 patients enroled after 7 yrs from index surgery or without follow-up later than 7 yrs post-surgery (n = 912 hips) 465 unilateral patients with all required data and visits at least 1 yr apart (n = 465 hips) 24 patients with blood metal ion levels below the detectable limit (n = 24 hips)
441 unilateral patients with all required data, visits at least 1 yr apart, and blood metal ion levels above the detectable limit (n = 441 hips) THA. In addition, there had to be a minimum of one year between visits, and the blood metal ion levels had to be above the system's detection limit. Finally, patients with developmental dysplasia of the hip were excluded. The final study consisted of 435 patients ( Fig. 1) (Table I) . Statistical analysis. First, the early and mid-term levels of metal ions in the blood were compared in a univariate fashion to assess change over time. A Wilcoxon signed-rank test was used. The outcome variables included the levels of Cr (parts per billion, ppb) and Co (ppb) ions and the Co/Cr ratio. In all analyses, the HRAs and THAs were considered separately. Secondly, we entered the change in each of the three metal ion levels in multivariable linear logistic regression models to evaluate which patient and implant related factors explained the changes in metal ion levels. The change was calculated for each patient subtracting the early followup value from the mid-term value. The time to the first measurement, the time between measurements, the value of the first measurement, gender, acetabular inclination, acetabular anteversion, age, size of the femoral head and the type of femoral stem in the THAs were defined as explanatory variables. The time to the first metal ion measurement, the time between measurements, and the value of the first measurement were defined as continuous variables. The other variables were defined as nominal. Commonly used cutoffs for acetabular inclination, anteversion, age, and femoral head size were used. Binary variables were age (< and ≥ 60 years of age) and head size using a 52 mm cutoff for men and a 48 mm cutoff for women. The angle of inclination was categorised into the following three groups: < 35º; 35º to 55º; and ≥ 55º. The angle of anteversion was categorised into three groups: < 20º; 20º to 40º; and ≥ 40º.
Odds ratios (OR) and 95% confidence intervals (CI) were calculated. A p-value of < 0.05 was considered significant. Statistical analyses were performed using SPSS Version 19.0 (SPSS Inc., Chicago, Illinois).
Results
The difference between the early and mid-term median values for Cr was pronounced for both types of implant (Table II) . This increase was significant for MoM HRA (p < 0.001) and MoM THA (p < 0.001) (Fig. 2a) . The values for Co for both MoM HRA (p < 0.001) and MoM THA (p < 0.001) also increased significantly at this time in univariate analysis (Fig. 2b ). This yielded a significant decrease in the Co/Cr ratio for both the MoM HRA (p < 0.001) and MoM THA (p = 0.039) implants (Fig. 2c) .
In a multivariable linear logistic regression with the change in the level of Cr ions as the outcome, the following explanatory variables were associated with the outcome in the HRA group: time between measurements (OR 0.62; 95% CI 0.17 to 1.07; p = 0.007), gender (OR 1.08; 95% CI 0.28 to 1.60; p = 0.006) (Fig. 3a) , and the initial Cr value (OR -0.32; 95% CI -0.51 to -0.13; p = 0.001). In the THA group, only the initial Cr value (OR -0.14; 95% CI -0.28 to MoM, metal-on-metal; HRA, hip resurfacing arthroplasty; THA, total hip arthroplasty; N/A, not applicable -0.01; p = 0.033) was associated with change in the level of Cr ions (Table III) . In a multivariable linear logistic regression model, female gender was the only variable to be associated with the change in the level of Co ions in the HRA group (OR 1.42; 95% CI 0.54 to 2.30; p = 0.002) (Fig. 3b) . In a similar analysis of change in Co ions in the THA group, only the initial Co value (OR -0.44; 95% CI -0.56 to -0.32; p < 0.001) was associated with the outcome (Table III) .
The final variable to be assessed by multivariable linear logistic regression was the change in the Co/Cr ratio. For the HRA group, only the initial ratio (OR -0.81; 95% CI -0.95 to -0.67; p < 0.001) was associated with this variable. Similarly, in the THA group only the initial ratio (OR -0.57; 95% CI -0.67 to -0.46; p < 0.001) was associated with the change in the Co/Cr ratio between the early and mid-term follow-up.
Discussion
Measurements of the levels of metal ions in the blood have been widely used as diagnostic tools for patients with MoM implants due to their relative low cost. As patients with second generation MoM implants enter the latter stages of follow-up, it is important to determine guidelines for a followup regimen that is best suited to each patient. Currently, no such recommendations exist, and the data on mid-term changes in the levels of metal ions are sparse and inconsistent. 7, [9] [10] [11] [12] [13] [14] [15] [16] Our aims were to determine whether measurements of metal ions in the blood change during extended follow-up, and whether specific cohorts of MoM patients merit closer follow-up than others. We found that for patients with both MoM HRAs and MoM THAs the levels of both Co and Cr ions increase between early and midterm follow-up. Moreover, we found that women with a MoM HRA have a higher risk of an increase in the level of metal ions in the blood.
The levels of Cr ions showed a distinct and consistent increase over time in both groups (Fig. 2a) . This finding is in conflict with several studies looking at both early 9,10 and mid-term 11,12,17 follow-up. For patients with both a MoM HRA and a MoM THA the change was negatively associated with the initial value in a multivariable model. This suggests that we might expect to see the groups approach a common asymptote as we follow them over time. Such a trend, however, is not yet clear in our patients at this time. There was a disparity between the genders in the MoM HRA group in the rates of Cr increase. The change for women was 1.0 ppb over two years, while for men it was only 0.3 ppb during this time. Several studies have shown a difference between the genders in levels of Cr ions at a single time point, [18] [19] [20] but none to our knowledge have shown such a difference in the later stages of follow-up. This finding is of particular interest in the light of recently published findings that women with increased level of Cr ions have worse health-related quality of life and hip function. 21 For the MoM THA group, however, we are unable to recommend a subgroup that warrants closer follow-up as no patient-or implant-related factors were shown to be significant in our multivariable model. Our observed increase in the level of Co ions is less straightforward. In our analysis of the MoM HRA group, while the change was statistically significant, it only consisted of a change of 1.0 ppb over two years. However, as was the case with Cr ions, the change becomes more clinically relevant if we consider gender separately. For women, the change was 2.7 ppb, and for men it was 0.5 ppb. This A disparity between the genders in the levels of Co ions has been confirmed by some authors 19, 20 although there is some contradictory evidence. 18 No studies to our knowledge have reported a significant increase in the levels of Co ions over time for patients with a MoM HRA implant.
For the MoM THA group, while we found a significant increase between visits of 0.7 ppb over two years, the initial level of Co ions was negatively associated with change in a multivariable logistic regression model. Outlier values of Co ions may have increased significantly between visits. However, as no demographic or surgical variables proved significant in predicting Co change in our multivariate model, we were unable to identify an at risk cohort based on such variables. To our knowledge, an increase in the level of Co ions for MoM THA patients at mid-term follow-up in the literature is inconsistent. As is the case in the literature about MoM HRA, most authors have found an increase which peaks at one year and then either stabilises or decreases. [13] [14] [15] [16] A study considering 254 ASR XL THAs found a significant increase in the levels of Co ions at early follow-up. 7 While both the levels of Co and Cr ions increased, the Co/Cr ratio decreased over time for both groups. This suggests either a faster rate of generation of Cr ions or a faster rate of clearance of Co ions in these patients at this time. In patients with a MoM THA, it has been suggested that a high Co/Cr ratio is indicative of taper corrosion, 22 ,23 and we have found that at both visits the median ratio was more than one. This suggests a substantial contribution of taper corrosion in this cohort, although the magnitude of that contribution appears to decrease with the passage of time. A biomechanical reason for the relative increase of Cr ions Graph showing the a) changes in the levels of chromium (Cr) ions in the blood from early to mid-term follow-up; b) changes in levels of cobalt (Co) ions in the blood from early to mid-term follow-up; c) changes in Co/Cr ratio from early to mid-term follow-up. Error bars display 95% confidence intervals (ppb, parts per billion; MoM, metal-on-metal; HRA, hip resurfacing arthroplasty; THA, total hip arthroplasty). compared with Co ions in MoM HRAs has yet to be suggested. Finally, we found that the position of the acetabular component was not associated with changes in the levels of metal ions. This is somewhat unexpected, however, it is not unreasonable that a variable that affects the levels of metal ions at a single time point does not predict change over time. While there are several studies that show that the orientation of the acetabular component is predictive of the levels of metal ions in the early post-operative period, 19, [24] [25] [26] [27] to our knowledge, there are none that have shown this association at longer follow-up.
Although the observed median differences are not currently clinically relevant, this change highlights a trend that patients are increasing as a group. This goes against the idea that there are two types of patients: those that can tolerate a MoM arthroplasty and those that cannot. We found that stringent follow-up is required even for those that appear to have safe clinical parameters seven years postoperatively. While most arthroplasties (223 MoM HRA and 136 MoM THA) remained in the safe zone of levels of metal ions (5 ppb), a median change of 0.5 ppb, for instance, means that 50% have increased more than that over the follow-up period. This makes it likely that the threshold of the safe level of ions will be breached by many over the course of the arthroplasty's lifetime. If we use the cutoffs for the levels of metal ions established by Van Der Straeten et al 28 (4.6 ppb for Cr and 4.0 ppb for Co), even in our short follow-up of two years, 12 patients with a HRA and 30 with a THA went from having safe levels to having unsafe levels. In contrast to other studies, [11] [12] [13] [14] [15] [16] [17] we show that the shedding of metal particles has not reached a state of equilibrium.
This study has limitations. First, the cohort consists only of patients whose arthroplasties survived for at least seven years. Therefore, these patients have done relatively well, particularly as far as MoM devices are concerned. However, it is these patients, upon whom future follow-up protocols need to be based. Secondly, none of our patients had a revision procedure after their second visit, so we were *denotes a p-value < 0.05 N/A, not applicable unable to correlate changes in the level of metal ions with the risk of revision. A total of 111 patients were excluded from the analysis as they were revised before the second visit. Various reasons for revision were reported, the most common being pain (75, 67.6%), soft-tissue changes identified on MRI (61, 58.6%) and patient demand (40, 36.0%). A total of 30 (27.0%) were revised for high levels of metal ions. Finally, our study was limited to ASR arthroplasties only, and given the ASR's unique design, these results should not be extrapolated to other MoM devices. Future studies should continue to document changes in the levels of metal ions in patients who have a MoM arthroplasty with the goal of defining specific follow-up protocols for the appropriate governing bodies to recommend. It is important to establish whether the levels of metal ions are trending towards an asymptotic value as our analysis suggests, and if so, to determine what that value will be. This is especially important in MoM HRAs, whose use is still warranted in carefully selected patients. 29, 30 It will also be important to correlate changes in the levels of metal ions with soft-tissue changes and revision. One study reported that progressive ALTR is correlated with the levels of metal ions, 31 while another found the opposite. 32 In conclusion, we found that the levels of Co and Cr ions in the blood increase from early to mid-term follow-up in patients with large head (> 40 mm) MoM arthroplasties. Our analysis of the MoM HRA group showed a larger increase for women in both the levels of Co and Cr ions, and that for men, the increase in Co ions is probably clinically negligible. While we found that levels of Co and Cr ions also increase significantly for patients with a MoM THA as a whole, we were unable to identify a subgroup that warrants closer follow-up with the variables that we collected. We recommend that the levels of metal ions be measured regularly for all patients with a MoM arthroplasty, although men with a MoM HRA may require less vigilance.
Take home message:
-Blood metal ion levels show significant trends of increasing in patients with ASR of the hip at mid-term follow-up.
-For MoM HRA there appears to be a gender discrepancy whereby women are at greater risk of having elevated metal ion levels, and are also at greater risk of these increasing throughout the follow-up period.
-Vigilant follow-up is recommended as the ion levels of patients with MoM bearings may cross the danger threshold at mid-term follow-up.
